The Role of Aeromonas Species as Enteropathogens in Patients with Inflammatory Bowel Disease
Abstract
Background/Aims Aeromonas species are Gram-negative, flagellated bacilli suggested to be associated with inflammatory bowel disease (IBD) flare-ups, but their precise role remains controversial. This retrospective study investigated Aeromonas as an enteropathogen in patients with IBD. Methods This study analyzed patients who tested positive for Aeromonas via stool multiplex PCR at Kangdong Sacred Heart Hospital between June 2023 and May 2025. Results Among the overall IBD cohort, Aeromonas was detected in 11/94 patients (11.7%; five with ulcerative colitis and six with Crohn's disease), identifying it as the second most prevalent pathogen, closely following Clostridioides difficile (14.9%, 14/94). This positivity rate was significantly higher than the 3.6% (111/3,056) observed in patients without IBD (p<0.001). IBD patients showed significantly lower PCR cycle threshold values (34.68±4.5 vs. 39.24±4.5, p=0.004), indicating a higher abundance of genetic material. Conclusions In conclusion, Aeromonas positivity is significantly more prevalent in IBD patients and is associated with a higher abundance of genetic material and inflammatory markers. Nevertheless, it is unclear if Aeromonas, acting as an enteropathogen, directly triggers acute flare-ups or is merely a consequence of a pre-existing compromised mucosal environment in patients with IBD.